Neumora modifies KOASTAL-2/-3 MDD studies, delays data to 2026; R&D head departs

Neumora Therapeutics, Inc.

KOASTAL-2/-3 paused, resume March 2025; topline data from KOASTAL-3 in Q1 2026 and -2 in Q2 2026.
Phase 2 bipolar depression trial for navacaprant discontinued to prioritize KOASTAL program.
Robert Lenz, M.D., Ph.D., head of R&D, leaving company; will serve in advisory role.
Cash, cash equivalents and marketable securities $307.6M as of Dec 31, 2024, funding into mid-2026.
Q4 2024 net loss $58.8M vs $108.7M Q4 2023; full year net loss $243.8M vs $235.9M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.